CELU · Celularity Inc
$0.88
+0.08 (+9.94%)
At close · Aug 26
Going-concern doubt
— flagged Apr 30, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our historical operating results indicatesubstantial doubt exists related to our ability to continue as a going concern.”View the 10-K filed Apr 30, 2026
Market Cap
$23.18M
Shares
28.95M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$26.55M
-51%
FY2025
Net Income
-$91.72M
-58.4%
FY2025
Gross Margin
29.66%
+39.1pp
FY2023
Operating Margin
-230.92%
-160.2pp
FY2025
Diluted EPS
-$3.59
-36%
FY2025
Operating Cash Flow
-$13.25M
-107.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| — | $26.55M | $54.22M | $22.77M | $17.98M | $21.34M | $14.28M | — | |
| — | $20.07M | $14.99M | $16.02M | — | — | — | — | |
| — | — | — | $6.76M | -$1.69M | $11.68M | $9.35M | — | |
| — | — | — | 29.66% | -9.4% | 54.76% | 65.46% | — | |
| — | $15.03M | $17.39M | $30.47M | $78.36M | $88.35M | $52.71M | — | |
| — | $51.27M | $58.64M | $50.58M | $66.02M | $71.34M | $31.34M | — | |
| — | $1.49M | $1.75M | $2.19M | $2.19M | $2.19M | $3.39M | — | |
| — | $7.3M | $7.92M | $9.32M | $9.44M | $8.82M | $8.17M | — | |
| — | -$61.31M | -$38.36M | -$192.29M | -$25.6M | -$109.06M | -$151.93M | -$1.68M | |
| — | -230.92% | -70.75% | -844.44% | -142.42% | -511.17% | -1064.05% | — | |
| — | -$54.01M | -$30.44M | -$182.96M | -$16.16M | -$100.24M | -$143.75M | — | |
| $209.08K | — | — | — | — | — | $1.78M | $3.75M | |
| — | -$30.41M | -$19.53M | -$4M | $39.81M | $8.96M | -$61.01M | $8.23M | |
| — | -$91.71M | -$57.89M | -$196.29M | $14.21M | -$100.1M | -$212.93M | $6.55M | |
| — | $3000 | — | $10K | $13K | $20K | -$4.7M | $668.23K | |
| — | -$91.72M | -$57.89M | -$196.3M | $14.19M | -$100.12M | -$208.23M | $5.88M | |
| — | -345.45% | -106.77% | -862.04% | 78.95% | -469.27% | -1458.42% | — | |
| — | -$91.8M | -$57.89M | — | — | — | -$3.93M | -$217.55K | |
| — | -$91.71M | -$57.9M | -$196.15M | $14.2M | -$100.12M | — | — | |
| USD/shares | — | -$3.59 | -$2.64 | -$11.02 | $1.01 | -$14.90 | — | — |
| USD/shares | — | -$3.59 | -$2.64 | -$11.02 | $0.95 | -$14.90 | — | — |
| shares | — | 25.6M | 21.89M | 17.81M | 13.99M | 6.71M | 1.84M | 2.55M |
| shares | — | 25.6M | 21.89M | 17.81M | 14.98M | 6.71M | 1.84M | 2.55M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.28×
EV/EBIT
—
P/E (TTM)
—
Peer median 3.11×
Peer medians compare against the 252 similar-size Biotechnology companies (of 534 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Degenerative Disease | $17,311,000 | $48,392,000 | $17,330,000 | $12,463,000 | $15,813,000 | $8,722,000 |
| Biobanking | $5,432,000 | $5,140,000 | $5,441,000 | $5,512,000 | $5,522,000 | $5,556,000 |
| Cell Therapy | $3,807,000 | $688,000 | — | — | — | — |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Product | $13,175,000 | $35,336,000 | $13,149,000 | $3,749,000 | $3,801,000 | $6,854,000 |
| License Royalty and Other | $7,943,000 | $13,744,000 | $4,181,000 | $8,714,000 | $12,012,000 | $1,868,000 |
| Service | $5,432,000 | $5,140,000 | $5,441,000 | $5,512,000 | $5,522,000 | $5,556,000 |
Key facts
CIK
1752828
CUSIP
151190204
13F (30d)
35 filings
35 filers
Visit website
Investor relations